ArticleMedeniyet medical journal2025
Biomarkers of the Complement System in Cancer.
Article in Medeniyet medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The insider's perspective: The intracellular complosome and immune cell dynamics in cancer.Clinical and translational medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cancer is a disease characterized by an unregulated division of abnormal cells in the body. The discovery of oncogenes and tumor suppressor genes has paved the way for the targeted use of individual biomarkers and proteins in cancer therapy. The signaling pathways in cells are closely linked, and research into these connections would lead to more precise personalized treatments for cancer. An imbalance in the complement system is associated with the development and progression of cancer. Comparable variations in gene expression and common complement biomarkers in different cancer types are poorly understood. This study aims to gain insights into biomarkers linking the complement system to carcinogenesis. Methods: Clinical and transcriptome data from the cancer genome atlas were used to analyze differentially expressed genes involved in the complement system in different cancer types. Various bioinformatics and machine learning techniques were used to suggest complement pathway-related carcinogenesis biomarkers. Results: This study provides a comprehensive elucidation of component 7 (C7), complement factor-D (CFD), interleukin-11 (IL11), apolipoprotein C1 (APOC1), and integrin binding sialic acid protein (IBSP) proteins as common biomarkers associated with the complement system in cancer and highlights the diagnostic and prognostic potential of these biomarkers. Conclusions: These biomarkers would pave the way for targeted cancer treatments in the context of precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.